Although small in scale relative to the size of the acquiring company, midsize acquisitions are becoming increasingly important to creating value in the biopharmaceutical industry. Realizing that value, however, requires a carefully customized approach to postmerger integration. Learn the six lessons that have emerged from BCG-supported acquisitions.
Having outperformed the overall capital market in recent years, medical-technology companies now face sizable shifts in the health care environment that will dictate fundamental changes in their operating model.
When competing in a new class of drugs, is it better to be the first to market or the best in class? BCG’s Ulrik Schulze and Michael Ringel explore this topic in the June 2013 issue of Nature Reviews Drug Discovery.